---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-248083"
form_type: "8-K"
ticker: "BMEA"
cik: "0001840439"
company_name: "Biomea Fusion, Inc."
filed_at: "2024-10-31T23:59:59+00:00"
generated_at: "2026-05-30T07:39:00.870641+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Biomea Fusion: icovamenib boosts GLP-1 therapy insulin secretion; new oral GLP-1 RA BMF-650 shows early promise

## Summary
- Preclinical ex vivo human islet data show icovamenib combined with tirzepatide or semaglutide more than doubles glucose-stimulated insulin secretion under hyperglycemic conditions.
- Phase II COVALENT-211 study combining icovamenib with a GLP-1-based therapy planned to begin in 2025.
- New oral small-molecule GLP-1 RA candidate BMF-650 exhibited higher bioavailability, less variable PK; estimated human dose ~100 mg once daily.
- In cynomolgus monkeys, BMF-650 improved glucose control and significantly suppressed appetite over a six-day dosing period.
- BMF-650 also enhanced glucose-stimulated insulin secretion in human donor islets, supporting potential for diabetes and obesity treatment.

## SEC filing metadata
- accession: 0001193125-24-248083
- form_type: 8-K
- ticker: BMEA
- cik: 0001840439
- company_name: Biomea Fusion, Inc.
- filed_at: 2024-10-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840439/000119312524248083/0001193125-24-248083-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840439/000119312524248083/d850084d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-248083
- JSON: https://secwatch.observer/filing/0001193125-24-248083.json
- Plain text: https://secwatch.observer/filing/0001193125-24-248083.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.